Scroll to Top

Stocks In Buzz: Janus Capital Group Inc. (NYSE:JNS), Symantec Corporation (NASDAQ:SYMC), Navidea Biopharmaceuticals Inc. (NYSEMKT:NAVB)

Posted in Business, Health7 months ago • Written by Robert JohnsonNo Comments

Dallas, Texas, 09/29/2014 (ustrademedia) – Janus Capital Group Inc. (NYSE:JNS) recently announced that a bong guru Bill Gross will join the company effective, Monday, September 29, 2014. Mr. Gross will join the company from Pimco, where was serving as Chief Investment Officer. Mr. Gross founded and served for more than four decades at Pimco. Mr. Gross was about to be fired from Pimco because of his increasingly erratic behavior, reported CNBC. Mr. Gross also met with Jeffrey Gundlach to discuss joining DoubleLine, a fixed income investment management firm. At Janus, Mr. Gross will manage the recently launched Global Unconstrained Bond Fund and related strategies, effective October 6, 2014.

Symantec Corporation (NASDAQ:SYMC) recently announced the appointment of its Interim CEO Michael Brown as CEO. Prior, Symantec fired then CEO Steve Bennett about six months ago and was searching for a suitable candidate since then. In his promoted role, Slump in PC sales has crimped sales of Symantec antivirus software. The firm is struggling with its business and has seen a series of leadership changes in the recent past. While the company helped pioneer anti-hacking software technologies, it is failing to match the pace with the security industry. Mr. Brown will share the strategic plan for the company in the next 30-day period.

Navidea Biopharmaceuticals Inc. (NYSEMKT:NAVB) announced that the European Medicines Agency’s CHMP (Committee for Medicinal Products for Human Use) has adopted a ‘positive’ opinion. While recommending the marketing authorization grant for Lymphoseek® 250 mg kit for radiopharmaceutical preparation in the EU. Navidea’s Interim CEO, Michael Goldberg expressed that the positive CHMP opinion brings Lymphoseek close to becoming the only “sentinel lymph node detection agent” approved in EU’s all 28 member countries. Lymphoseek is differentiated in its ability to help more effectively stage cancer by being accurate and reliable in locating sentinel lymph nodes draining a tumor in several types of cancer.

TAGS: , , , , , , , , , , , ,

Leave A Response